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ABSTRACT
Objectives: Assessing the safety and eﬃcacy of immune checkpoint inhibition in risky cancer
patient subgroups: pre-existing organ failure, elderly, presence of auto-immune disease,
transplanted patients and brain metastasis treated with immune checkpoint inhibitors.
Methods: PubMed, Web of Science and Google scholar databases were searched for English
articles published prior to February 2019. Search terms used were organ failure, dialysis,
elderly, organ transplant, liver disease, auto-immune disease, immunosuppression, and brain
metastasis.
Results: Our literature data indicate that immune checkpoint inhibition in the majority of
these subpopulations can be administered safely without any loss of eﬃcacy. These data are
mostly based on case-reports as only a minority of high-risk patients were included in (the
earliest) clinical trials. Validation of these results is necessary on a larger scale.
Conclusion: Future trials should not automatically exclude aforementioned patient groups
but alter the study design and make their inclusion possible, since more data are needed to
answer several remaining questions in these populations. Especially since ICI appears to be
safe to administer in these patients.
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Introduction
Immune checkpoint inhibition (ICI) has been vali-
dated as a standard treatment regimen in hemato-
logic malignancies and numerous solid cancer
types. Well-known immune checkpoints are cyto-
toxic T-lymphocyte–associated antigen 4 (CTLA-4)
and programmed death 1 (PD-1) (and its ligand
PD-L1) [1]. These functions as negative regulators
of the T-cell immune function, restraining over-
activity of the immune system by inducing T cell
anergy and/or apoptosis. Inhibition of these
immune checkpoints thus results in an over-
activity of the immune system by enhancing
a T-cell response and, subsequently, an anti-tumor
response by increased tumor antigen recognition
[2]. On the other hand, the immune checkpoint
pathways have an important immune regulatory
function that, when suppressed by ICI, induce auto-
immune phenomena that can aﬀect every organ.
Indeed, ICI has a distinct toxicity proﬁle and
although generally well tolerated in most patients,
some experience rare, life-threatening side-eﬀects
(immune-related adverse events, irAEs Table 1). As
indications for ICI are broadening, this implies that
a larger and heterogeneous population will be trea-
ted. This will confront the physician not only with
a more challenging population to treat, but also
with an increasing incidence of irAEs that need
immediate and adequate medical attention [3].
Numerous clinical trials are ongoing to assess the
eﬃciency and safety of ICI for various malignancies,
but data are lacking information on high-risk
patient groups that are prone to develop more
and/or worse irAEs, and hence therapy-related wor-
sening of their general health status. In this review,
we will discuss some risky patient groups and the
current knowledge of ICI-treatment in these set-
tings. We will consider patients with pre-existent
organ injury or failure, elderly (active) auto-
immune disease(s) (AID), transplanted patients (kid-
ney or liver) and patients suﬀering from brain
metastasis.
Method
Search strategy
A comprehensive search was performed on Google
scholar, Pubmed and Web of Science for selecting
relevant literature and studies from inception of ICI
until February 2019. A set of keywords and combina-
tion of keywords were applied during the literature
study: ‘ICI’ or ‘immune checkpoint inhibition’ was
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combined with any of the following terms: ‘organ
failure’, ‘dialysis’, ‘elderly’, ‘organ transplant’, ‘liver
disease’, ‘auto-immune disease’, ‘immunosuppres-
sion’, and ‘brain metastasis’. In review articles, the
reference list was consulted and using the snowball
eﬀect, other English studies or articles were added.
The earliest studies were published in February 2015
and all articles were initially screened by title and
abstract. Articles were withheld when each relevant
patient group was treated with one or more immune
checkpoint inhibitors, when authors used the stan-
dardized evaluation of tumor response to the ICI
according to the RECIST/iRECIST guidelines and
when adverse events were graded based on the
National Cancer Institute Common Toxicity Criteria
(version 4.0 or later).
Results
Organ comorbidities
Kanz et al. [17] performed a multicenter retrospective
analysis to detect changes in organ dysfunction and
evaluate response rate (RR), progression-free survival
(PFS) and irAE-incidence in anti-PD-1 treated cancer
patients with baseline organ dysfunction. The latter was
deﬁned as renal insuﬃciency (glomerular ﬁltration rate of
≤30 ml/min or serum creatinine level ≥2 mg/dl), cardiac
Table 1. Overview of IrAEs per organ system, divided by commonly and rarely reported events [4–16].
Organ system Commonly reported irAEs Rarely reported irAEs
Dermatologic – Maculopapular rash/dermatitis
– Lichenoid rash/dermatitis
– Vitiligo
– Pruritus
– Bullous pemphigoid
– Alopecia
– Steven Johnson syndrome
– Toxic epidermal necrolysis
Gastro-intestinal – Diarrhea
– Colitis
– Panenteritis
– Pancreatitis
– Nausea
– Vomiting
Endocrinal – Hypothyroidia
– Hyperthyroidia
– Thyroiditis
– Hypophysitis
– Adrenal cortical insuﬃciency
– Diabetes
Hepatic – Serum transaminases elevation
– Hepatitis
Pulmonary – Pneumonitis – Sarcoid-like granulomatosis
– Pleuritis
Renal – (Interstitial) nephritis
– Serum creatinine elevation
– Lupus-like nephritis
– Minimal change disease
– Thrombotic microangiopathy
Rheumatic – Myalgia
– Arthralgia
– Arthritis
– Dermatomyositis
– Polymyalgia rheumatic
– Sjögren syndrome
– Drug-induced lupus nephritis
– Lymphocytic vasculitis
– Polymyositis
– Polyarticular inﬂammatory arthritis
– Inﬂammatory myopathy
– Eosinophilic fasciitis
Ophthalmologic – Uveitis
– Conjunctivitis
– Keratoconjunctivitis sicca
– (Epi)scleritis
– Blepharitis
– Neuroretinitis
Neurologic – Aseptic meningitis
– Encephalitis
– Myasthenia gravis
– Necrotizing myositis
– Acute/chronic peripheral neuropathy
– Immune demyelinating polyradiculoneuropathy
– Transverse myelitis
– Posterior reversible leukoencephalopathy
Hematologic – Immune thrombocytopenic purpura
– Hemolytic anemia
– Hemophagocytic lymphohistiocytosis
– Aplastic anemia
– Pure red cell aplasia
Cardiac – Myocarditis
– Pericardial eﬀusion
– Pericarditis
– Congestive heart failure
– Takotsubo cardiomyopathy
– Arrhythmias
– Conduction disease
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dysfunction (left ventricular ejection fraction ≤45%) or
hepatic dysfunction (serum transaminases or bilirubin
>3x upper limit of normal or evidence of cirrhosis on
imaging). They reported no signiﬁcant increase in irAE-
incidence. Also, worsening organ dysfunction occurred
sporadically and resolved spontaneously with supportive
care in all cases. The authors concluded that anti-PD-1
administration can be considered safe in patients with
organ dysfunction, provided appropriate clinical monitor-
ing is performed during the treatment period.
Hertz et al. [18] described four case-reports of
patients with chronic kidney failure who all were trea-
ted with ICI (anti-CTLA-4/anti-PD-1). None of these
patients experienced further deteriorating kidney
function during treatment, nor was any kidney toxicity
observed. One patient-developed grade 2 polyneuro-
pathy, which however resolved after adequate ther-
apy was started.
The data from our own research group (unpub-
lished) also indicate no signiﬁcant signs of kidney
damage during ICI treatment (immune-related nephri-
tis were not included in the analysis), based on serum
creatinine, Cystatin C, proteinuria, albuminuria, immu-
noglobinuria (IgG) measured in 18 mRCC patients.
Statistical analysis needs to be ﬁnalized but a ﬁrst
glance at the data revealed no signiﬁcant alterations
in these markers during ICI treatment [19].
Next, not many cases have been reported of end-
stage renal disease (ESRD) patients undergoing dialysis
and receiving ICI treatment. Two ESRDpatients suﬀering
from mCCRCC were administered nivolumab. Both
patients had a signiﬁcant anti-tumor response accord-
ing to iRECIST-criteria and did not experience any irAEs
[20]. Cavalcante et al. [21] described another two ESRD
patients with metastatic melanoma who received and
beneﬁted from ipilimumab treatment: a partial response
was noted in one patient while the second patient
achieved complete remission of the disease. Toxicity
was acceptable, though one patient encountered
a grade 3 skin irAE (bullous pemphigoid) which resolved
under systemic corticosteroids. Lastly, a single-center
case series from Park et al. [22] treated four ESRD
patients with PD-1 inhibitors: two patients with mRCC
and two patients with unresectable cutaneous squa-
mous cell carcinoma. Although all patients experi-
enced a signiﬁcant anti-tumor response according to
iRECIST-criteria, toxicity was moderately high. Two inci-
dences of grade 2 fatigue, one grade 2 rash, one grade 3
pneumonitis and even a fatal incidence of grade 4 acute
encephalitis occurred.
In short, the available literature shows that hepatic,
renal and cardiac comorbidities nor need for dialysis
should be an absolute contra-indication for administering
ICI in cancer patients, provided the standard of care and
organ function monitoring is adequately performed.
Elderly and poor performance status
Not only are elderly more susceptible of developing
organ comorbidities (hypertension, hypercholestero-
lemia, chronic kidney disease), assumptions have
been made that they are aﬀected by immunosenes-
cence, an age-related functional decline in the
immune system. This may be associated with
a decreased auto-immunity, a signiﬁcant functional
(anti-cancer) immunodeﬁciency and a dysregulation
of the diﬀerent immune system components, both
innate and acquired. In a 2016 systematic review
and meta-analysis by Nishijima et al. [23] ICI eﬃcacy
and tolerance was compared between young and old
patients (cut-oﬀ 65/70 years). They concluded that
tolerance of immunotherapy in older patients is simi-
lar compared to young patients and that disease-free
survival (DFS) and overall survival (OS) were consis-
tently better in both treated groups. Regarding
response, Nishijima et al. made a pre-speciﬁed sub-
group analysis by age and type of ICI treatment (anti-
PD-1 agents vs. anti-CTLA-4 agents) of four trials each.
Elderly (≥65) years treated with anti-CTLA-4 agents
had a signiﬁcant increase in OS as well as younger
patients (<65 years). In the anti-PD-1 treated patients,
four trials reported an increased survival outcome in
patients <65 years and 65–75 years old, but not in
≥75-year-old patients. This is probably attributed to
a lack of statistical power and heterogeneity of the
used populations [23]. Contradictory, a retrospective
study from Ibrahim et al. [24] reported a signiﬁcantly
higher ORR and PFS in elderly (≥75 years) with meta-
static melanoma treated with pembrolizumab in
comparison to those patients treated with nivolumab
or ipilimumab. Toxicity was similar in all ICI treated
patients.
In patients with poor performance status (PS), a meta-
analysis of Bersanelli et al. [25] stated that PS does not
interfere with ICI eﬃcacy as an identical OS beneﬁt was
noted in patients with poor (ECOG) PS (= 1) compared to
normal PS (= 0). As patients with a PS = 2 were mostly
refused in participating in clinical trials with ICI, data
regarding this subgroup is scanty. However, a recent
multi-variant analysis in nivolumab treated NSCLC
patients observed that PS was an independent prognos-
tic factor in OS when comparing patients with PS = 1 and
PS = 2 versus patients with PS = 0 [26]. Then again,
a retrospective study from Muchnik et al. [27] concluded
that PS primarily aﬀects OS in ICI treated NSCLC patients
as older (≥70 years): patients with PS = 0 or PS = 1 were
observed to have similar beneﬁts from ICI when com-
pared with young patients in healthier conditions, while
older patients with PS ≥2 hadworse outcome despite ICI-
treatment. All authors conclude that large-scale prospec-
tive studies remain necessary to assess safety and eﬃcacy
of ICI in these fragile subpopulations.
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Organ transplant patients
Administration of ICI in organ-transplanted patients is
another debatable subject. The PD-1 and CTLA-4
pathways are vital down regulators of auto-immunity
as they restrict T-cell activation. Thus, activation of
these pathways by ICI could enhance or trigger
organ transplant rejection. Also, transplanted patients
have a lasting need for chronic immunosuppression
[28]. For these reasons, organ-transplanted patients
are excluded from studies in which treatment with
ICI is indicated. Chae et al.’s [29] research suggest
that CTLA-4 inhibitors are relatively safe in patients
with solid organ transplant, as only one of six patients
experienced allograft rejection. PD-1 inhibitors on the
other hand, are signiﬁcantly more prone to trigger
allogeneic graft rejection, as this occurred in four
out of eight patients [29]. Another case-report of
a patient with a pre-emptive renal allograft transplant
and under chronic immunosuppression (prednisone,
10 mg), who was diagnosed with metastatic mela-
noma, showed that treatment with nivolumab
resulted in renal allograft rejection 1 week after
administration. Nivolumab treatment was ceased but
renal function remained irreversibly impaired, leading
to urgent dialysis need. Nivolumab treatment was
again introduced and triggered an important regres-
sion of tumor burden. Furthermore, no irAEs occurred
after the patient became dialysis dependent [30].
There is still insuﬃcient evidence to presume that
ICI is safe in allogeneic-transplanted cancer patients.
Abovementioned results tend to point out that CTLA-
4 inhibitors are more favorable than anti-PD-1 in this
population, though these ﬁndings should be further
validated in a larger prospective studies., Authors con-
cur that the gain in life expectancy with ICI treatment
should be weighed up against the possible and prob-
able occurrence of irAE development and organ rejec-
tion, and this should be discussed with patient and
organ specialist [23].
Auto-immune diseases
Cancer patients with an active autoimmune disease
(AID) are a challenging population to treat with ICI.
These patients are almost invariably excluded from
clinical trials because of possible exacerbation of the
preexisting auto-immune disease, increased incidence
of (more severe) irAEs and the theoretical projection
of reduced cancer response rate due to intake of
chronic immunosuppressants.
A meta-analysis from Abdel-Wahab et al. [31] ana-
lyzed case reports of cancer patients (N = 123) with
auto-immune diseases who were subjected to treat-
ment with ICI. They found that 50% had AID exacer-
bation and 34% had de novo irAEs, with colitis and
hypophysitis being most frequently reported.
Nine percent of patients experienced both. However,
this did not result in a permanent discontinuation of
the ICI in any of the subjects.
Recently, a retrospective analysis of 46 NSCLC
(stage IIIb/IV) patients with AID, treated with anti-
PD-1 was published. The authors concluded that the
incidence of worsening AID-related symptoms during
ICI was relatively low, as only 17% of patients experi-
enced exacerbation of their AI-status. Twenty-six per-
cent of patients developed one or more irAEs non-
directly associated to their AID, but no grade 3 or 4
irAEs were reported. Three patients had to discon-
tinue anti-PD-1 treatment permanently due to intol-
erable toxicity. In retrospect, the irAE incidence in
patients with AID does not diﬀer signiﬁcantly from
an anti-PD-1 treated populations without AID [32].
These results were somewhat contradicted by
Danlos et al. [33] as anti-PD-1 treated cancer patients
with pre-existing AID did encounter more irAEs and
ﬂare-ups when prospectively compared to AID-free
patients. Though grade ≥2 irAEs incidence was com-
parable with other investigations. No diﬀerences in OS
were observed in both patient groups.
Menzies et al. [34] also reported an increase of
immune toxicity during anti-PD-1 treatment in mela-
noma patients with active AI disease or early treat-
ment with ipilimumab, although these toxicities are
perceived as mild, easily manageable under adequate
corticosteroid treatment, and did not require therapy
discontinuation. Importantly, it should be mentioned
that signiﬁcant clinical response rates were achieved
in this patient population. We conclude that some
discrepancies regarding incidence of ICI toxicity and
AID ﬂare-ups exist between diﬀerent studies, though
safety and eﬃciency can be similar in AID-patients as
non-AID patients when adequate clinical monitoring
is warranted.
Brain metastasis
Brain metastatic (BM) patients (here we focus on asymp-
tomatic patients, treated with radiotherapy or under
minimal dose systemic steroids) have a poor prognosis
and are often excluded from enrolment in trials with
immune checkpoint blockers. The checkmate 017 and
057 trials compared treatment with docetaxel or nivo-
lumab in previously treated NSCLC with BM and found
no OS beneﬁt of nivolumab over docetaxel in this sub-
group. (HR: 1.04, 95% CI: 0.62–1.76) [35]. On the other
hand, the OAK study compared atezolizumab with doc-
etaxel in platinum-failed patients with advanced/meta-
static NSCLC, including supratentorial metastatic
patients. An increased survival outcome of atezolizumab
over docetaxel was noted (HR: 0.54, 95% CI: 0.31–0.94)
[31]. Both ICI demonstrated a tolerable safety proﬁle
that was comparable to prior studies and also to doc-
etaxel [35,36].
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An abstract from Albiges et al. [37] described
a prospective analysis (NIVOREN) to assess the
response to nivolumab in BM RCC. This was the ﬁrst
study that included RCC-patients with BM, irrespective
of local control for BM. Nivolumab proved more eﬃ-
cient in BM patient without prior local treatment
compared to pre-treated patients, and most patients
in the latter group required local treatment due to
progression. The six-months brain progression free-
survival was 44.8% in previously treated patients in
comparison to 24.5% in non-treated patients.
Regarding melanoma, an Australian, multicenter
open-label, randomized phase II-study from Long et al.
[38] investigated the eﬃcacy of ICI in melanoma patients
with active BM. Eventually, one concluded that the com-
bination ipilimumab/nivolumab as well as nivolumab in
monotherapy showed intracranial response in BM mela-
noma, although the combination being superior com-
pared to nivolumab in monotherapy: in asymptomatic
BM patients, a 46% intracranial response rate with the
combination ipilimumab/nivolumab was noted, while
this was 20% in patients that were administered nivolu-
mab alone. The six-month progression-free survival (PFS)
was 53% and 20%, respectively [38]. The Checkpoint 204
trial conﬁrmed these results, as an intracranial response in
41/75 patients (55%) treated with ipilimumab/nivolumab
combination was observed, and a 6 months PFS of 67%
was noted [39]. Toxicity was obviously higher in the
nivolumab/ipilimumab combination cohort than in the
nivolumabmonotherapy cohort, with a 97% and 50–68%
irAE prevalence, respectively, while grade 3–4 irAEs were
present in 54% and 13–16%, respectively [38].
Discussion and conclusion
This review focuses on the safety and eﬃciency of ICI
(anti CTLA-4, anti PD1 and anti PD-L1) in subgroups of
cancer patients: those with fragile health conditions,
those considered to have an increased risk to therapy-
induced auto-immune phenomena and other adverse
events, patients with brain metastasis and patients
that are excluded from inclusion in the larger ICI trials
because of the abovementioned conditions. Evidently,
there remain subpopulations that have not been
addressed suﬃciently in literature, and hence have
not been discussed in this review paper (immunode-
prived patients, e.g. HIV, patients with chronic infec-
tions such as hepatitis B/C or latent tuberculosis, ICI
during pregnancy)
Regarding (non-auto-immune related) organ
comorbidity and ICI, it has been described in the
current literature that anti-PD-1 is considered safe in
these patients. The eﬀectiveness of ICI in patients with
renal impairment has also been examined in
a number of clinical trials. Preliminary results indicate
similar response rates in ICI treated cancer patients
with or without renal impairment. However, these
data need to be further validated in the future [40–
42]. Exacerbation of baseline organ dysfunction was
never found to be attributable to ICI treatment, and
worsening could be reversed by standard supportive
measure. It must be clear that the risk of all other ICI
should also be assessed, especially when administer-
ing an ICI combination therapy.
We do believe that the use of ICI is a valid and safer
option in comparison to chemotherapy in patient
with multiple, complex organ comorbidities.
Although only a handful of case reports exist, these
data suggest that ESRD patients undergoing dialysis
may indeed beneﬁt from ICI treatment as the majority
of patients had signiﬁcant anti-tumor response.
A plausible explanation is that the high molecular
weight of ICI prevents them from being removed
during dialysis, though further pharmacokinetic ana-
lysis is obligatory. Toxicity was quite manageable in
this patient group, but some subjects did develop
severe irAEs (two grade 3 and one fatal grade 4).
Based on the limited sample size, there is insuﬃcient
evidence to state that toxicity of ICI is higher in ESRD-
patients than in patients with normal renal function.
From a theoretical point of view, there is also no
reason to suspect higher risk of ICI toxicity in this
population though caution remains well advised.
Current and future prospective studies will eventually
provide us with an adequate answer.
Based on the current literature, ICI may be carefully
considered in transplanted patients, though this should
always be in consent with the patient as the risk of
inducing organ rejection when administering ICI exists
and may have life-threatening consequences [31].
Management of patients with auto-immune dis-
ease or patients under chronic immunosuppression
remains delicate when considering treatment with
immune checkpoint inhibition. Some studies acknowl-
edge active autoimmune disease as a contraindication
for immune checkpoint inhibition, but a > 2-year
interval of only inactive disease or chronic treatment
with low-dose corticosteroids (e.g. prednisolone
≤10 mg/day) could be considered safe [26]. Either
way, this ﬁeld of research requires more robust, long-
term prospective studies to fully appreciate the inter-
actions between immune checkpoint inhibition and
auto-immune disease and/or chronic immunosup-
pression [32].
As mentioned earlier, elderly patients are subjected
to an increased risk of developing (age-related) comor-
bidities but also immunosenescence, which could limit
tumor recognition and elimination by diminished T-cell
mediated immunity and therefore, a decreased anti-
tumor immune response [23]. Theoretically, this could
imply that immune checkpoint inhibitors can be less
eﬃcacious in this particular group. Based on the current
available literature there seems to be no signs of higher
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toxicity range in the elderly. Elderly (≥65 years) did
obtain a similar survival beneﬁt from ICI compared to
younger patients, but some discrepancies in literature
exist considering the use of anti-PD-1 agents in ≥75
years old patients. This needs to be further elaborated
[23,24]. Regarding ECOG PS, the clinical beneﬁt from ICI
in patients with PS ≥ 2 seemed to be inferior compared
to PS < 2, while other research states that PS is an
independent prognostic factor. Nonetheless, there is
a high need for large prospective studies that do not
exclude these vulnerable patient groups from ICI treat-
ment [25–27].
It should also be mentioned that even minor ICI
induced toxicity in these patients with worse baseline
organ function can induce higher risk of major organ
dysfunction. Nonetheless, age and frailty (PS ≤ 2)
should not guide physicians to disallow ICI in patients
with metastatic malignancies as they still may truly
beneﬁt from this therapy. Future trials should never
neglect these subpopulations, but we advise caution
and ensure extra medical monitoring during treat-
ment with ICI [43].
These last few years, more andmore brain metastatic
patients have been treated with immune checkpoint
inhibitors, with varying results. Although this barrier
has now been overcome and more and more positive
results reported, brain metastatic patients presenting
with active, untreated disease and/or experiencing clin-
ical symptoms are still excluded from most clinical trials
due to the poor prognosis and the risk of early death.
Current state-of-the-art indeed shows a signiﬁcant trend
towards intracranial response and an increased progres-
sion-free survival with immune checkpoint inhibitors
(with results in melanoma being the most promising,
especially the anti-CTLA4 – anti PD1 combination).
Nevertheless, high-risk brain metastatic patients (symp-
tomatic or evidence of leptomeningeal metastasis) are
generally excluded from most studies which limit our
conclusions regarding ICI in brain metastatic patients.
Immune checkpoint inhibitors have proven to be
of major impact in current cancer therapeutic strategy
for various cancers. Based on the current data avail-
able, we can state that ICI treatment in the above
described high-risk subpopulations may be consid-
ered eﬃcacious and safe, but the all-encompassing
answer still has to be found. We encourage clinicians
and investigators to adopt a personalized approach
for each cancer patient by assessing the risks and
beneﬁts of (not) receiving ICI. Hence, future trials
should not automatically exclude these high-risk
patients but should adapt the study design so that
more info becomes available about these patients,
that transcends the limits of case reports. In this
point of view, the SAUL trial is a large prospective,
multi-centric, single-arm study of atezolizumab for
locally advanced or metastatic urothelial carcinoma
of the urinary tract that enrolled a broader patient
population including patients with an ECOG PS of 0–2,
stable CNS metastasis, AID, active steroid treatment,
renal dialysis requirement or creatinine clearance of
<15 ml/min. This is a research design that we encou-
rage clinicians to implement in the near future [44].
Additionally, biomarker development for detection
of irAEs is an area of investigation that is extensively
being studied by various research groups. Although
this topic falls beyond the scope of this review, devel-
opment of adequate biomarkers could aid the oncol-
ogist in guiding his patient to a more beneﬁcial
outcome during ICI treatment and is therefore highly
recommended [45].
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